Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$24.40 USD

24.40
2,150,803

+0.60 (2.52%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $24.39 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

Zacks Equity Research

Why Is Acadia (ACAD) Up 9.7% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y

by Zacks Equity Research

ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -42.11% and 1.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Zacks Equity Research

TEVA Gears Up to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) third-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products.

Zacks Equity Research

Humana (HUM) Gears Up for Q3 Earnings: What Awaits the Stock?

by Zacks Equity Research

Humana's (HUM) third-quarter 2020 results are likely to reflect elevated expenses and lower net investment income, partially offset by a growing membership base.

Zacks Equity Research

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio

by Zacks Equity Research

ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.

Zacks Equity Research

ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

by Zacks Equity Research

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

by Kinjel Shah

Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.

Zacks Equity Research

Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Zacks Equity Research

Humana (HUM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Humana's (HUM) Q2 results are likely to reflect better revenues and membership growth.

Zacks Equity Research

Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Zacks Equity Research

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Sorrento (SRNE) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

Zacks Equity Research

Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

Zacks Equity Research

ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

Zacks Equity Research

Axcella (AXLA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.

Zacks Equity Research

Soleno (SLNO) to report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.